Program
BRL-301
A development code.
Its studies are mostly in Lupus Erythematosus, Systemic · Lymphoma, B-Cell, led by BRL Medicine.
Furthest: no phase, since Apr 19, 20233 company-led studies, 3 open or runningNext primary completion: Aug 15, 2027
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| BRL Medicine | 33 open or running | no phasesince Apr 19, 2023 | Apr 19, 2023 | Aug 15, 2027NCT07248163 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 19, 2023First study: no phase study in Lupus Erythematosus, SystemicFirst studyNCT05859997 · 15 planned · China
- Aug 4, 2023No phase study in Lupus Erythematosus, SystemicNCT05988216 · 12 planned · China
- Nov 18, 2025No phase study in Non-hodgkin Lymphoma,B CellNCT07248163 · 6 planned · China
Ahead
- Aug 15, 2027Primary completion: no phase study in Non-hodgkin Lymphoma,B CellNCT07248163
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07248163Non-hodgkin Lymphoma,B Cell · China | – | Recruiting | Aug 15, 2027 | 6 |
| NCT05988216Lupus Erythematosus, Systemic · China | – | Recruiting | Dec 2024 | 12 |
| NCT05859997Lupus Erythematosus, Systemic · China | – | By invitation | May 27, 2024 | 15 |
How it is read
Names in the registry
- “BRL-301”, 3 entries
Codes read as this program: BRL301.
Conditions, from the studies’ own filings
- Lupus Erythematosus, Systemic, 2 studies
- Lymphoma, B-Cell, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.